| SET 2,3 NEAR TERM USE CASES | COMPLETED STUDIES | STUDIES UNDERWAY/ UNDER CONSIDERATION |
|---|---|---|
| Prognostic for chemotherapy benefit and independent from/ complementary to existing prognostic tests | SWOG-S8814 | CALGB-9741 (Dec 2021), RxPonder 1Q23 |
| Prognostic for neo-adjuvant therapy benefit | Z1031 | ALTERNATE (1Q23) |
| Prognostic for benefit from extended endocrine therapy | NSAPB-42 (4Q22) | |
| Prognostic for benefit from ckd 4/6 inhibitor treatment | CCTG MA-38 | PALLET (1Q22)** |
| PALLAS (1Q23) | ||
| Prognostic for benefit from PI3 kinase inhibitor treatment | SWOG-S1207 (1Q23) | |
| SET 2,3 LONG TERM USE CASES | STUDIES UNDERWAY/ UNDER CONSIDERATION |
|
| Prognostic for class of endocrine therapy uses | AMEERA-6 (2026) | |
| Prognostic for benefit from ovarian function suppression | IBCSG SOFT/IBCSG TEXT | |
| Improve endocrine therapy adherence | TBD | |
| Prognostic for benefit from lifestyle changes/weight loss | BWEL-A011401 |